Global Blood Therapeutics – Consensus Indicates Potential 93.2% Upside

Broker Ratings

Global Blood Therapeutics found using ticker (GBT) have now 19 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 138 and 45 and has a mean target at 82.11. Given that the stocks previous close was at 42.49 this now indicates there is a potential upside of 93.2%. The day 50 moving average is 43.64 and the 200 moving average now moves to 47.97. The company has a market capitalisation of $2,639m. You can visit the company’s website by visiting:

Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Global Blood Therapeutics - Consensus Indicates Potential 79.3% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index